ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 139 filers reported holding ACCELERON PHARMA INC in Q3 2016. The put-call ratio across all filers is 1.27 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $21,961,000 | -41.1% | 175,000 | -36.4% | 0.75% | -10.2% |
Q1 2021 | $37,293,000 | -31.4% | 275,000 | -35.3% | 0.83% | -35.8% |
Q4 2020 | $54,374,000 | -3.4% | 425,000 | -15.0% | 1.29% | -40.2% |
Q3 2020 | $56,265,000 | -1.6% | 500,000 | -16.7% | 2.16% | -0.8% |
Q2 2020 | $57,162,000 | -22.9% | 600,000 | -27.3% | 2.18% | -36.7% |
Q1 2020 | $74,143,000 | +7404.4% | 825,000 | +3200.0% | 3.44% | +5641.7% |
Q3 2019 | $988,000 | -39.9% | 25,000 | -37.5% | 0.06% | -36.2% |
Q2 2019 | $1,643,000 | -11.8% | 40,000 | 0.0% | 0.09% | -25.4% |
Q1 2019 | $1,863,000 | -12.2% | 40,000 | -17.9% | 0.13% | -26.7% |
Q4 2018 | $2,121,000 | -25.9% | 48,695 | -2.6% | 0.17% | -7.5% |
Q3 2018 | $2,862,000 | -17.7% | 50,000 | -30.2% | 0.19% | -27.6% |
Q2 2018 | $3,477,000 | +24.1% | 71,667 | 0.0% | 0.26% | +23.0% |
Q1 2018 | $2,802,000 | -12.0% | 71,667 | -4.4% | 0.21% | -37.2% |
Q4 2017 | $3,183,000 | +13.7% | 75,000 | 0.0% | 0.33% | -32.6% |
Q3 2017 | $2,799,000 | +22.8% | 75,000 | 0.0% | 0.49% | +30.7% |
Q2 2017 | $2,279,000 | +14.8% | 75,000 | 0.0% | 0.38% | +31.2% |
Q1 2017 | $1,985,000 | -39.0% | 75,000 | -41.2% | 0.29% | -34.2% |
Q4 2016 | $3,253,000 | -29.5% | 127,451 | 0.0% | 0.44% | -13.9% |
Q3 2016 | $4,612,000 | +6.5% | 127,451 | 0.0% | 0.51% | -17.1% |
Q2 2016 | $4,331,000 | -17.9% | 127,451 | -36.3% | 0.61% | -22.8% |
Q1 2016 | $5,278,000 | -45.9% | 200,000 | 0.0% | 0.80% | -31.9% |
Q4 2015 | $9,752,000 | +95.8% | 200,000 | 0.0% | 1.17% | +46.8% |
Q3 2015 | $4,980,000 | -21.3% | 200,000 | 0.0% | 0.80% | -5.5% |
Q2 2015 | $6,328,000 | -2.2% | 200,000 | +17.6% | 0.84% | -15.9% |
Q1 2015 | $6,470,000 | -33.6% | 170,000 | -32.0% | 1.00% | -33.4% |
Q4 2014 | $9,740,000 | -19.5% | 250,000 | -37.5% | 1.50% | -39.6% |
Q3 2014 | $12,096,000 | +78.0% | 400,000 | +100.0% | 2.49% | +38.2% |
Q2 2014 | $6,794,000 | – | 200,000 | – | 1.80% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |